Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) InvestigationBusiness Wire • 02/21/23
Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic ProtoporphyriaPRNewsWire • 12/27/22
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)PRNewsWire • 10/31/22
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates SBCF, PFHD, BBQ, GMTXPRNewsWire • 08/22/22
GEMINI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTXBusiness Wire • 08/13/22
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Gemini Therapeutics, Inc. MergerNewsfile Corp • 08/11/22
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZPRNewsWire • 08/11/22
GMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire • 08/11/22
Gemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 04/12/22
Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire • 11/15/21
Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development SummitBusiness Wire • 10/19/21
Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business Wire • 10/14/21